Last €8.28 EUR
Change Today +0.392 / 4.97%
Volume 0.0
XYXR On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 11:58 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

raptor pharmaceutical corp (XYXR) Snapshot

Open
€8.08
Previous Close
€7.88
Day High
€8.28
Day Low
€8.04
52 Week High
02/20/14 - €13.87
52 Week Low
04/28/14 - €5.33
Market Cap
526.0M
Average Volume 10 Days
160.0
EPS TTM
--
Shares Outstanding
63.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RAPTOR PHARMACEUTICAL CORP (XYXR)

raptor pharmaceutical corp (XYXR) Related Bloomberg News

View More Bloomberg News

raptor pharmaceutical corp (XYXR) Related Businessweek News

No Related Businessweek News Found

raptor pharmaceutical corp (XYXR) Details

Raptor Pharmaceuticals Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. It markets PROCYSBI, a delayed-release capsule used for the management of nephropathic cystinosis in adults and children six years and older in the United States. The company also commercializes PROCYSBI in the 28 member states of the European Commission plus Norway, Liechtenstein, and Iceland. Its clinical development products include RP103 used as a treatment for Huntington's disease; RP103 as a treatment for non-alcoholic fatty liver disease in children; and RP103 as a treatment for mitochondrial disorders, including Leigh syndrome. The company’s other clinical-stage product candidate is Convivia, an oral formulation of 4-methylpyrazole for the treatment of acetaldehyde toxicity resulting from aldehyde dehydrogenase deficiency. Its preclinical programs comprise cysteamine dioxygenase and HepTide for the treatment of hepatocellular carcinoma and other cancers susceptible to induced lysosomal storage. Raptor Pharmaceuticals Corp. has a collaboration agreement with DaVita Clinical Research to screen blood samples from the United States patients with end-stage renal disease to identify patients with unrecognized late-onset nephropathic cystinosis. The company was founded in 2005 and is headquartered in Novato, California.

70 Employees
Last Reported Date: 03/17/14
Founded in 2005

raptor pharmaceutical corp (XYXR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $350.0K
Chief Business Officer
Total Annual Compensation: $292.0K
Compensation as of Fiscal Year 2013.

raptor pharmaceutical corp (XYXR) Key Developments

Raptor Pharmaceuticals Corp. Announces Executive Appointments, Effective January 12, 2015

Raptor Pharmaceuticals Corp. announces that appointment of Krishna R. Polu as its Chief Medical Officer and Michael P. Smith as Chief Financial Officer, effective January 12, 2015. Dr. Polu will oversee all global clinical development programs, medical affairs and other related functions. Mr. Smith will serve as company’s principal financial and accounting officer. Both will report to Julie Anne Smith, company’s President and Chief Executive Officer. Dr. Polu most recently served as Chief Medical Officer at CytomX Therapeutics. Michael Smith most recently served as Catalyst Biosciences Chief Financial and Business Advisor. Prior to that, he was Vice President of Business Development at iPierian and Chief Financial Officer for Memory Pharmaceuticals where he oversaw all finance, business development, strategic planning, intellectual property and site operation activities.

Raptor Pharmaceuticals Corp. Appoints egg Lapointe and Georges Gemayel to Board of Directors, Effective January 1, 2015

Raptor Pharmaceutical Corp. announced the appointment of Gregg Lapointe and Georges Gemayel, Ph.D. to its Board of Directors, effective January 1, 2015. As previously disclosed, they will be joining Julie Anne Smith, President and CEO-Designate as she succeeds Christopher Starr, Ph.D., as Chief Executive Officer and joins the Board effective January 1, 2015. Mr. Lapointe has nearly 20 years of experience in the pharmaceutical and medical device industries. Currently, he is Co-Founder and CEO of Cerium Pharmaceuticals. Dr. Gemayel has over 25 years of experience in the pharmaceutical industry, including management and executive positions spanning the U.S., Europe and the Middle East.

Raptor Pharmaceuticals Corp. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 09:10 AM

Raptor Pharmaceuticals Corp. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 09:10 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Julie Anne Smith, Chief Operating Officer and Executive Vice President of Strategy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XYXR:GR €8.28 EUR +0.392

XYXR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for XYXR.
View Industry Companies
 

Industry Analysis

XYXR

Industry Average

Valuation XYXR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.4x
Price/Book 33.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RAPTOR PHARMACEUTICAL CORP, please visit www.raptorpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.